Literature DB >> 6088663

Effect of MuLV-related genes on plasmacytomagenesis in BALB/c mice.

M Potter, J W Hartley, J S Wax, D Gallahan.   

Abstract

The role of spreading somatic cell infections with ecotropic MuLV viruses in the induction of plasmacytomas in BALB/cAN pi mice was determined by constructing congenic mice that lacked the gene locus Cv that codes for ecotropic virus. DBA/2 mice that lack Cv on chromosome (chr) 5 carry a closely linked gene Rmcfr that determines resistance to infection with mink cell focus-forming viruses (MCF). Rmcfr was retrogressively back-crossed onto BALB/c for six successive generations to produce N6 mice. N6 mice were mated to each other to produce BALB/c.DBA/2 Rmvfr/Rmcfr homozygotes. This stock of mice lacked Cv, as demonstrated by DNA hybridization and were as fully susceptible to developing plasmacytomas as the parental BALB/c. A second congenic stock BALB/c.DBA/2 Rmcfr/Rmcfr Fv-1n/Fv-1n was also developed, but the mice of this stock showed a reduced incidence of plasmacytomas, as did BALB/c.DBA/2 Fv-1n/Fv-1n mice. These findings indicated Fv-1 or a gene closely linked to it conferred partial resistance to plasmacytomagenesis. In constructing the BALB/c.DBA/2 Fv-1n/Fv-1n stock, a "control" congenic BALB/c.DBA/2 Fv-1b/Fv-1b was also developed at N6. Surprisingly, this stock carried the Qa2+ trait. These mice were also partially resistant to plasmacytomagenesis, suggesting a gene on chromosome 17 (the location of Qa2) or a gene located elsewhere that regulates Qa2 expression is linked to a gene controlling partial resistance to plasmacytoma development.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088663      PMCID: PMC2187450          DOI: 10.1084/jem.160.2.435

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  20 in total

1.  HISTOLOGY OF DEVELOPING PLASMA CELL NEOPLASIA INDUCED BY MINERAL OIL IN BALB/C MICE.

Authors:  M POTTER; R C MACCARDLE
Journal:  J Natl Cancer Inst       Date:  1964-09       Impact factor: 13.506

Review 2.  The Fv-1 gene of the mouse and its control of murine leukemia virus replication.

Authors:  P Jolicoeur
Journal:  Curr Top Microbiol Immunol       Date:  1979       Impact factor: 4.291

3.  Endogenous RNA tumor viruses are activated during chemical induction of murine plasmacytomas.

Authors:  M Y Armstrong; P Ebenstein; W H Konigsberg; F F Richards
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

4.  Analysis by immunoelectron microscopy of type-C viruses associated with primary and short-term transplanted mouse plasma cell tumors.

Authors:  T Aoki; M Potter; M M Sturm
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

5.  Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas.

Authors:  G S Payne; J M Bishop; H E Varmus
Journal:  Nature       Date:  1982-01-21       Impact factor: 49.962

6.  Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis.

Authors:  W S Hayward; B G Neel; S M Astrin
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

7.  A procedure for culture of cells from mouse tail biopsies: brief communication.

Authors:  M R Lander; B Moll; W P Rowe
Journal:  J Natl Cancer Inst       Date:  1978-02       Impact factor: 13.506

8.  Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas.

Authors:  S Ohno; M Babonits; F Wiener; J Spira; G Klein; M Potter
Journal:  Cell       Date:  1979-12       Impact factor: 41.582

9.  The requirement of an adherent cell substratum for the growth of developing plasmacytoma cells in vivo.

Authors:  M Cancro; M Potter
Journal:  J Exp Med       Date:  1976-12-01       Impact factor: 14.307

10.  A major genetic locus affecting resistance to infection with murine leukemia viruses. I. Tissue culture studies of naturally occurring viruses.

Authors:  T Pincus; J W Hartley; W P Rowe
Journal:  J Exp Med       Date:  1971-06-01       Impact factor: 14.307

View more
  7 in total

1.  Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis.

Authors:  B A Mock; M M Krall; J K Dosik
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

2.  Rapid induction of IgM-secreting murine plasmacytomas by pristane and an immunoglobulin heavy-chain promoter/enhancer-driven c-myc/v-Ha-ras retrovirus.

Authors:  R Clynes; J Wax; L W Stanton; S Smith-Gill; M Potter; K B Marcu
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

3.  Abnormalities induced by the mutant gene, lpr. Patterns of disease and expression of murine leukemia viruses in SJL/J mice homozygous and heterozygous for lpr.

Authors:  H C Morse; J B Roths; W F Davidson; W Y Langdon; T N Fredrickson; J W Hartley
Journal:  J Exp Med       Date:  1985-03-01       Impact factor: 14.307

4.  Insertional hypermutation in mineral oil-induced plasmacytomas.

Authors:  Gero Knittel; Mirjam Metzner; Gabriele Beck-Engeser; Ada Kan; Tomasz Ahrends; Dan Eilat; Konrad Huppi; Matthias Wabl
Journal:  Eur J Immunol       Date:  2014-09       Impact factor: 6.688

5.  Susceptibility of BALB/c mice carrying various DBA/2 genes to development of Friend murine leukemia virus-induced erythroleukemia.

Authors:  S Ruscetti; R Matthai; M Potter
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

6.  The endogenous mink cell focus-forming (MCF) gp70 linked to the Rmcf gene restricts MCF virus replication in vivo and provides partial resistance to erythroleukemia induced by Friend murine leukemia virus.

Authors:  R S Buller; M Sitbon; J L Portis
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

7.  Differential disease restriction of Moloney and Friend murine leukemia viruses by the mouse Rmcf gene is governed by the viral long terminal repeat.

Authors:  B K Brightman; Q X Li; D J Trepp; H Fan
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.